Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $8.4 million, down from $14.6 million in Q4 2024, primarily due to the government shutdown and procurement delays [24] - Product revenues decreased to $5.6 million from $12.6 million year-over-year, attributed to delays in product orders for U.S. Defense applications [24] - Non-product revenues increased to $2.5 million from $1.7 million, driven by the IVAS color MicroLED development program [25] - Cost of product revenue was $4.7 million, representing 83% of net product revenues, compared to $10.7 million or 84% in the previous year [26] Business Line Data and Key Metrics Changes - The defense programs remain the core of the business and the strongest growth driver, with ongoing supply for thermal weapon sight programs [12] - The company has seen increased demand for its products due to geopolitical conflicts, particularly in defense applications [5] - The partnership with Theon International has opened new opportunities in the European, Southeast Asian, and NATO defense markets, with sales commencing [8] Market Data and Key Metrics Changes - Increased defense budgets across NATO member states are driving growth expectations, particularly in Europe [10] - The U.S. Army's intent to procure over 1 million drones is expected to accelerate demand for the company's display and optical technologies [11] - The first-person drone market is projected to grow from under $300 million to $1.2 billion by 2030, indicating a 31% compound annual growth rate [11] Company Strategy and Development Direction - The company is transitioning from a legacy microdisplay company to a vertically integrated advanced technology platform [5] - The second phase of the transformation plan focuses on accelerating revenue growth, expanding customer reach, and innovating product offerings [20] - The company aims to leverage its unique position as the only manufacturer of four types of microdisplays to capture more orders in fast-growing segments [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from the government shutdown, citing a strong pipeline and strategic positioning [22] - The company provided conservative revenue guidance for 2026, estimating between $52 million and $60 million [22] - Management highlighted the importance of ongoing geopolitical tensions in sustaining defense spending and the evolution of warfare [16] Other Important Information - The company raised $56 million in capital from strategic and institutional investors, strengthening its balance sheet [4] - Automation investments are expected to deliver over $1 million in annual operating expense savings [17] - The company is actively engaged with stakeholders to ensure its technology is well-positioned for selection in upcoming defense contracts [13] Q&A Session Summary Question: What is the backlog as of December 31 and remaining performance obligations? - The backlog was approximately $37 million, with expectations to book larger orders soon [36] Question: Did delays from Q4 extend the MicroLED program completion into 2027? - The company is working towards completion this year, with technical milestones on track [39] Question: How should capacity needs be considered for the SBMC program? - The company has selected tooling equipment for production and believes it can meet capacity needs without further CapEx [43] Question: When will the $1 million in annualized savings from automation be achieved? - The company is already seeing operational expense savings from automation initiatives [45] Question: How does the company view the commercial open-market opportunity in the U.S. for drones? - There is surging demand for first-person viewers due to the FCC's DJI ban, with significant orders expected [50] Question: What is the outlook for the $450 billion reconciliation bill and its impact on microdisplays? - The company is actively seeking additional funding and expects positive outcomes from the budget discussions [53] Question: Are there new markets and technologies outside the defense industry? - The company plans to announce new products in new markets this year, which are currently under development [58]

Financial Data and Key Metrics Changes - Q4 2025 was the strongest revenue quarter of the year, with revenue up 32% over Q3 2025 and close to the prior year quarter's revenue level [6] - For the full year, pro forma cash basis EBITDA improved by 31% compared to 2024, with a 56% improvement in Q4 alone [6] - Gross margin improved to 40% for the year, up from 38% in 2024, reflecting a more disciplined approach [7] - Net operating results for 2025 improved by 23%, while GAAP net loss for Q4 2025 was impacted by significant one-time accounting-related non-cash charges totaling $6.3 million [8] Business Line Data and Key Metrics Changes - The revenue mix has diversified, reducing concentration on a single platform, with revenue now more balanced across Roblox, Minecraft, Fortnite, and mobile playable ads [9] - Mobile playables accounted for over 25% of revenue in Q4, ending the year at about 20%, while Roblox revenue diminished to under 40% of total revenue [32] Market Data and Key Metrics Changes - The U.S. digital advertising market is valued at $316 billion, with a gaming population of 200 million, yet total yearly spend in gaming remains under $10 billion, indicating a significant opportunity for growth [10] Company Strategy and Development Direction - The company aims to maintain a lower cost structure, expand scalable revenue streams, and focus on disciplined execution to achieve cash basis EBITDA profitability by year-end 2026 [14] - The acquisition of the Misfits Ads Division is expected to enhance revenue capabilities and contribute significantly to net revenue, potentially equating to 50% of 2025's net revenue [12][22] Management's Comments on Operating Environment and Future Outlook - Management expects Q2 2026 to show more meaningful progress as the benefits of the transformation from 2025 take hold, with cash basis EBITDA profitability within reach by year-end [9][13] - The company is optimistic about the long-term potential of digital assets and is actively evaluating opportunities in this area [13] Other Important Information - The company has a debt-free balance sheet with over $14 million in capital as of December 31, 2025, and has removed going concern language from the auditor's report [4] - The company is focused on integrating the Misfits Ads Division to leverage its capabilities and enhance overall strategy [45] Q&A Session Summary Question: Progression towards cash-based EBITDA profitability in 2026 - Management outlined a three-phase approach for 2026, expecting some lag in Q1, visible inflection in Q2, and delivery in the second half of the year [17][19] Question: Details on the Misfits acquisition and its impact - The acquisition is expected to consolidate complementary businesses and enhance revenue capabilities, with anticipated net revenue contribution equating to approximately 50% of 2025's net revenue [20][22] Question: Gross margin sustainability and progression - Management anticipates gross margins returning above 40% in Q2, with a focus on maintaining healthy margins despite seasonal pressures [24][39]

Financial Data and Key Metrics Changes - Q4 2025 revenue reached $13.4 million, a 30% increase compared to the same quarter last year, with full-year revenue of $44.1 million, up 35% from 2024 [5][22] - Adjusted EBITDA for Q4 was $4.8 million, up from $3.7 million in the prior year, representing 36% of revenues, while full-year adjusted EBITDA rose to $13.6 million, an 89% increase from $7.2 million the previous year [5][22] - Gross margins expanded to 77% year-over-year, driven by pricing improvements in consumables and reductions in system cost of revenue [22] Business Line Data and Key Metrics Changes - The company sold 624 UltraMIST systems in 2025, compared to 374 in the prior year, with Q4 sales of 255 systems marking a record high [5][22] - The dermaPACE and Profile product lines were sunset in Q4, leading to increased costs in goods sold and operating expenses [6] Market Data and Key Metrics Changes - The reduction in reimbursement prices for skin substitutes has significantly impacted the industry, with a 90%-95% price cut in a $15 billion category, affecting customer operations and growth rates [8][10] - The company noted a shift in customer dynamics, with some mobile wound providers dissolving while new ones are emerging, indicating a changing landscape in the market [12][20] Company Strategy and Development Direction - The company is focusing on expanding its active system base and engaging with new resellers to capitalize on market opportunities created by industry disruptions [13][14] - A new customer category termed "baby elephants" is emerging, consisting of small groups of practitioners looking to expand their operations significantly [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by CMS reimbursement changes but expressed optimism about the long-term market direction favoring evidence-based and cost-effective wound care solutions [20] - The company anticipates a gradual recovery in growth rates as the market stabilizes, with guidance for Q1 2026 revenues expected to be between $9.6 million and $10.3 million, reflecting a 3%-10% increase from the prior year [31] Other Important Information - A restatement of financials was completed, primarily related to previously unrecognized sales tax liabilities and revenue allocation errors, with a total revenue impact of approximately $300,000 [23] - The company is actively working with third-party tax advisors to strengthen compliance processes and controls [24] Q&A Session Summary Question: Can you speak about the anticipated selling cycle for inbound interests? - Management noted that the selling cycle has been stretched due to industry shock but is starting to improve as the market stabilizes [35] Question: What can be expected for adjusted EBITDA in 2026? - Management refrained from providing specific guidance but indicated that incremental revenue would likely drop around 50% to the EBITDA line [37] Question: How should growth rates be expected to trend after Q1? - Management expects the rest of the year to be better than Q1, but it is premature to break it down by quarter [41] Question: What is the current state of the commercial organization? - The internal sales force is being expanded, and the company is working with larger resellers, which could significantly enhance sales potential [43][44] Question: What updates are there on the new manufacturing line for applicators? - Management reported delays in qualifying the mold for the new manufacturing line but is hopeful for progress in the coming months [58]

Financial Data and Key Metrics Changes - Total clinic revenue for the full year reached $1,163 million, representing a 2% year-over-year growth [2] - Average revenue per customer rebounded significantly in Q4, reaching $316, an 11% increase year-over-year [3] - Net income attributable to shareholders grew 9% year-over-year to $51 million, and EPS increased 4% to $0.50 [5] - EBITDA was $70 million with an EBITDA margin of 40.4% [5] Business Line Data and Key Metrics Changes - The company operated 283 locations and served 6.63 million customers over the trailing twelve months [2] - Aesthetic dermatology accounted for 70% of the company's performance, while aesthetic surgery accounted for 30% [21] - The AGA hair loss treatment network has grown to become one of the largest in Japan, with expansions in orthopedics and fertility treatment [9][10] Market Data and Key Metrics Changes - The aesthetic dermatology market in Japan is growing at approximately 10% annually, while aesthetic surgery is growing at about 3% [21] - The domestic Japanese market for medical expenditures is valued at JPY 48 trillion, with the company aiming to capture at least 10% of this market [17] Company Strategy and Development Direction - The core strategic pillars include aesthetic dermatology, non-aesthetic healthcare, and global expansion, with a focus on longevity and AI-driven healthcare [6] - The company is launching SBC Wellness 2.0, an upgraded corporate wellness platform integrating biomarker analysis and AI-powered diagnostics [6][7] - The multi-brand strategy aims to capture diverse customer needs and maximize lifetime value per customer [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovering customer spending and growth in aesthetic medicine, with expectations of continued strong performance [14][15] - The company aims to achieve a number one position in Japan's market for various medical fields by 2035 [19] - AI is seen as a foundational pillar for growth and efficiency, with plans to deploy AI across multiple operational areas [11] Other Important Information - The company is actively considering M&A opportunities to strengthen its market position in Japan and abroad [27][28] - A share buyback program was approved, allowing for flexible repurchases if market conditions are favorable [39] Q&A Session Summary Question: What is the current status of the healthcare and aesthetic medicine market in Japan? - The aesthetic dermatology market is growing by 10% annually, while aesthetic surgery is growing at 3% [21] Question: Will SBC Wellness be a growth driver in fiscal year 2026? - SBC Wellness is not expected to be a large revenue driver initially, but aims to expand the customer base [22] Question: What operational improvements are expected from AI? - AI will enhance efficiency in headquarters and clinics, with a focus on creating success cases this year [26] Question: What is the company's M&A strategy? - The company aims to achieve a number one position in various medical fields by 2035 and will engage in M&A if good opportunities arise [27][28] Question: What are the next steps for the investment in OrangeTwist? - The company plans to leverage its expertise in aesthetic medicine and explore opportunities in the longevity market with OrangeTwist [29][31] Question: How will the company utilize its cash reserves? - The company has abundant cash for safe investments and plans to use it flexibly for M&A opportunities [35]

Financial Data and Key Metrics Changes - Net sales for 2025 totaled $118.4 million, a 7.6% decrease from $128.1 million in 2024. However, net sales for Q4 2025 were $3.3 million, reflecting a 5.9% increase from $28.6 million in Q4 2024 [11][12] - Gross margin percentage increased to 15.2% in 2025 compared to 13.1% in 2024. For Q4 2025, gross profit was $5.1 million or 16.7% of net sales, compared to $2.8 million or 9.9% in the same quarter of the previous year [14][15] - Adjusted EBITDA for Q4 2025 was $1.2 million, a significant improvement from a loss of $889,000 in Q4 2024. For the year ended December 31, 2025, adjusted EBITDA was $2.5 million, up from $2.1 million in 2024 [21][22] Business Line Data and Key Metrics Changes - Medical imaging net sales increased by $2.5 million or 6.7% in 2025 compared to 2024, with a $1.4 million increase in Q4 2025 compared to Q4 2024 [11][12] - Aerospace and Defense net sales decreased by $5 million in 2025 but increased by $1.1 million in Q4 2025 compared to the same quarter in 2024 [13] - Industrial net sales decreased by $4.6 million or 12.9% for the full year and by $607,000 or 7.7% in Q4 2025 compared to Q4 2024 [14] Market Data and Key Metrics Changes - Customer backlog increased to $77.3 million at year-end 2025, a 17.4% increase from $65.9 million at the end of 2024, indicating positive trends in customer orders [5][14] - The company is experiencing strong quoting activity as customers evaluate nearshore manufacturing strategies for North America and Asia [7] Company Strategy and Development Direction - The company is focused on strengthening its balance sheet and reducing inventory investments in 2026 while driving efficiencies in manufacturing processes to achieve sustainable long-term EBITDA growth [22][29] - Nortech is investing in new technologies and regulatory capabilities to leverage future growth, particularly in fiber optic and digital technologies [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about positioning in the nearshoring landscape and noted that restructuring activities have led to positive operational and financial results [29] - The company is closely monitoring trade policies and geopolitical uncertainties, particularly regarding tariffs, which could impact operations [9] Other Important Information - The company entered into new agreements with Associated Bank for a $2.2 million term note and a $15 million asset-backed line of credit, which is expected to lower borrowing costs and support business growth [6][22] - Cash totaled $1.7 million as of December 31, 2025, up from $916,000 a year earlier, reflecting improved cash flow management [17][18] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with management expressing anticipation for the next earnings report in May [31][32]

Financial Data and Key Metrics Changes - Q4 2025 was the strongest revenue quarter of the year, with revenue up 32% over Q3 2025 and close to the prior year quarter's revenue level [6] - For the full year, pro forma cash basis EBITDA improved by 31% compared to 2024, including a 56% improvement in Q4 alone [6] - Gross margin improved to 40% for the year, up from 38% in 2024, reflecting a more disciplined approach [7] - Net operating results for 2025 improved by 23%, while GAAP net loss for Q4 2025 was impacted by significant one-time accounting-related non-cash charges totaling $6.3 million [8] Business Line Data and Key Metrics Changes - The revenue mix has diversified, reducing concentration on a single platform, with revenue now more balanced across Roblox, Minecraft, Fortnite, and mobile playable ads [9] - Mobile playables accounted for over 25% of revenue in Q4 2025, ending the year at about 20%, while Roblox revenue diminished to under 40% of total revenue [32] Market Data and Key Metrics Changes - The U.S. digital advertising market is valued at $316 billion, with a gaming population of 200 million, yet total yearly spend in gaming remains under $10 billion, indicating a significant opportunity for growth [10][11] - Consumers spend approximately 11.8 hours per week playing video games, nearly as much time as on social media and streaming [10] Company Strategy and Development Direction - The company aims to maintain a lower cost structure, expand scalable, repeatable revenue streams, and focus on disciplined execution [14] - The acquisition of the Misfits Ads Division is expected to enhance revenue capabilities and contribute significantly to cash basis EBITDA profitability [12][22] Management's Comments on Operating Environment and Future Outlook - Management expects Q1 2026 revenue to be ahead of Q1 2025, with a consistent pipeline and average deal size above $200K [13] - The full financial impact of the changes made in 2025 is not yet reflected in reported results, with expectations for more meaningful progress beginning in Q2 2026 [13] Other Important Information - The company has a debt-free balance sheet with over $14 million in capital as of December 31, 2025, and has removed going concern language from the auditor's report [4] - The company is actively evaluating opportunities related to digital assets while remaining optimistic about long-term potential [14] Q&A Session Summary Question: Progression towards cash-based EBITDA profitability in 2026 - Management outlined a three-phase approach for 2026, expecting Q1 to show some lag, Q2 to reflect a visible inflection, and the second half to focus on delivery [17][18] Question: Details on the Misfits acquisition and its impact - The acquisition is expected to consolidate complementary businesses and provide access to a profitable revenue stream, with anticipated net revenue contribution equal to approximately 50% of 2025's net revenue [22][23] Question: Gross margin sustainability and progression - Management anticipates gross margins returning above 40% in Q2 2026, with a focus on maintaining healthy margins despite seasonal pressures [25][39]

Financial Data and Key Metrics Changes - In 2025, the company recognized $74.3 million in revenue from AUCATZYL, with a net product revenue of $23.3 million for Q4 2025 [4][34] - The total revenue for Q4 2025, including a $1 million license revenue component, was $24.3 million [34] - Cost of sales for Q4 2025 was $25.3 million, significantly higher than $11.4 million in Q4 2024, primarily due to a full quarter of sales and increased manufacturing expenses [34][37] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million in Q4 2024 [39] Business Line Data and Key Metrics Changes - The company achieved regulatory approvals in the EU and the U.K. by the end of 2025, initiating the launch of AUCATZYL in the U.K. at the beginning of 2026 [5][4] - The company is targeting over 80 activated centers by the end of 2026, building on the 67 centers activated by the end of 2025 [4] Market Data and Key Metrics Changes - The company does not expect significant contributions from the U.K. or other EU countries in 2026, as it is still early in the launch process [55] - The company is in discussions with market access authorities in Europe to evaluate appropriate paths for market entry [55] Company Strategy and Development Direction - The company aims to drive market share for Obe-cel, improve gross margins, and expand the utility of Obe-cel through ongoing clinical trial programs [50] - The company is focusing on broadening the product's indications, including pediatric patients and autoimmune diseases [13][14] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for 2026, expecting net revenue of $120 million to $135 million and a shift to positive gross margins [4][45] - The company anticipates that current cash equivalents and marketable securities will fund operations into Q4 2027 [45] Other Important Information - The company is conducting several studies, including the CATULUS study for pediatric patients and the LUMINA study for lupus nephritis, with pivotal data expected in 2027 and 2028 respectively [17][48] Q&A Session Summary Question: What is the expected contribution from the U.K. and other regions for the 2026 guidance? - The company does not plan to break out revenue contributions from the U.K. or other EU countries, as it is early in the launch process [54] Question: How is the LUMINA enrollment progressing? - The LUMINA study is gaining momentum, with U.S. centers expected to come online soon [63] Question: What are the expectations for gross margin evolution once it turns positive? - The company aims to drive down production costs through increased volume and operational optimization [86] Question: Will there be early data disclosures from ongoing studies? - The company does not plan to release early data from pivotal studies to maintain the integrity of the trials [75][76]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $0.5 million, with $0.4 million from U.S. sales of 25 Symvess units, and total revenue for the year was $2.0 million, with $1.4 million from U.S. sales of 61 Symvess units [17][22] - Net loss for Q4 2025 was $24.8 million, compared to a net loss of $20.9 million for Q4 2024, while the net loss for the year was $40.8 million, significantly reduced from $148.7 million in 2024 [23] - Cash and cash equivalents stood at $50.5 million as of December 31, 2025, with additional funding raised post-quarter [24] Business Line Data and Key Metrics Changes - The commercial launch of Symvess has seen 27 hospitals ordering the product, with a reorder rate from these hospitals [5][8] - Q4 product sales for Symvess were $0.4 million, with a total of $1.4 million for the year, indicating initial traction in the market [5][17] - The company has received a $1.475 million purchase commitment for clinical evaluation in Saudi Arabia, indicating international expansion efforts [7] Market Data and Key Metrics Changes - The success rate for VAC submissions for Symvess is approximately 70%, with 27 VAC approvals in the U.S. and 43 additional reviews ongoing [5][30] - The company is engaging with group purchasing organizations (GPOs) to streamline the contracting process, which could enhance market penetration [31] Company Strategy and Development Direction - The company is focused on expanding the commercialization of Symvess into international markets, including Saudi Arabia and Israel, while also advancing other bioengineered vessel programs [4][7] - Plans to submit a supplemental BLA for dialysis access in the second half of 2026, contingent on positive interim results from ongoing trials [15][35] - The company is also preparing for first-in-human studies for its coronary tissue engineered vessel (CTEV) later in 2026 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the positive response to the new pricing of Symvess at $17,000, which aligns it competitively with other vascular products [30] - The company anticipates continued growth in adoption rates for Symvess, driven by positive clinical outcomes and surgeon feedback [32][56] - Management acknowledged the challenges in the biotech financing market but emphasized a focus on reducing cash burn and exploring business development opportunities [75][78] Other Important Information - The company has initiated a credit facility providing up to $77.5 million in new financing, which includes an initial tranche of $40 million [24] - The company is actively working on training military surgeons to utilize Symvess, leveraging funding from the U.S. Department of Defense [62] Q&A Session Summary Question: How are sites responding to the new pricing of Symvess? - Management noted a positive response to the $17,000 price point, leading to higher VAC approval rates and increased usage [30] Question: What are the expectations for trauma adoption in the coming year? - Management indicated it is too early to guide but noted that the price change and published long-term data have positively impacted adoption [32] Question: How important is the sales cycle in relation to SG&A? - Management is focusing on expanding the sales team domestically while also partnering for international commercialization efforts [40] Question: What is the expected revenue flow from contracts in Saudi Arabia? - Initial orders are expected to be chunky, with a strategy to distribute products across multiple medical centers [52] Question: What is the status of VAC approvals and their conversion to procurement? - Management indicated that the lower price point has improved the speed of getting products on shelves post-VAC approval [66] Question: Will the pricing in Saudi Arabia differ from the U.S.? - Management anticipates that pricing in Saudi Arabia may be higher than the U.S. due to additional logistics and distribution costs [68]

Financial Data and Key Metrics Changes - In 2025, gross written premiums (GWP) reached CNY 7.4 billion, a 21% increase year-over-year, while first-year premiums (FYP) grew 35% to CNY 4.6 billion [5][15] - Total revenue for the year was CNY 1.6 billion, reflecting a 27% growth from the previous year [6][15] - Non-GAAP net profit was CNY 222.6 million, marking the third consecutive year of profitability [6][15] - Operating expenses increased by 3.4% year-over-year to CNY 415 million, while the expense to income ratio improved by 5.9 percentage points to 26.3% [20] Business Line Data and Key Metrics Changes - Long-term insurance products accounted for over 90% of total GWP, with FYP from long-term savings products surging 48% to CNY 3.5 billion [16] - FYP for annuity products more than doubled year-over-year to CNY 1 billion, driven by demand for wealth management solutions [16] - The average ticket size for long-term savings products rose 37% year-over-year to CNY 103,000 [19] Market Data and Key Metrics Changes - The international business, particularly in Singapore and Vietnam, showed strong performance, with GWP in Vietnam increasing by 106% and revenue by 84% year-over-year [12][21] - The number of insurance policies issued in Vietnam increased by 31% year-over-year, with the IFA business seeing a quadrupling of active platform users [21] Company Strategy and Development Direction - The company aims to deepen AI deployment across its business to enhance service quality and user experience [13] - Focus on product innovation in core growth areas, particularly in long-term health insurance and wealth management [13] - Plans to accelerate international expansion through Poni Insurtech, increasing overseas revenue contribution [13] Management's Comments on Operating Environment and Future Outlook - The insurance industry in China is experiencing structural changes, with a shift towards long-term stable assets like insurance due to declining bank deposit rates [4] - The company is well-positioned to capitalize on these trends and expects continued growth in both domestic and international markets [24] - Management expressed confidence in sustaining growth momentum despite regulatory changes in Hong Kong [29][30] Other Important Information - The company launched new products, including a participating annuity and customized medical insurance products, to meet diverse customer needs [8] - AI solutions have been integrated across the customer journey, significantly enhancing user experience and operational efficiency [9][20] Q&A Session Summary Question: Operating costs grew faster than revenue; how will the company improve this? - Management explained that the growth in operating costs relative to revenue is due to the revenue mix, with international revenues having lower gross margins [28] Question: How does Huize plan to sustain growth in Hong Kong amid regulatory changes? - Management noted that while there is a dampening effect on the brokerage market, the underlying demand for offshore products remains strong, and they expect growth momentum to persist [29][30] Question: Opportunities for margin expansion beyond AI? - Management reiterated that margin compression is linked to the revenue mix and that AI deployment is expected to improve gross margins in the future [39][40] Question: Why is the stock not reflecting the fundamentals? - Management indicated that market pessimism and the switch to a half-yearly reporting schedule may have contributed to the stock's performance, despite strong growth in fundamentals [41][42]

Financial Data and Key Metrics Changes - Full year gross billings reached $127.6 million, representing a year-over-year growth of 83.4%, while net revenues grew 88.6% year-over-year to $95.6 million [4] - Net operating cash inflow surpassed the $10 million mark, reaching $11.8 million in 2025, indicating a sustainable business model [5] - Q4 net revenue was $30.6 million, an 88.6% increase from the same quarter last year [6] - Q4 gross billings grew by 72.0% from the same quarter last year to $36.8 million [7] - Q4 operating loss was $5.2 million, while net loss attributable to ordinary shareholders was $6.5 million, reflecting significant increases of 504.3% and 368.8% respectively from the same quarter last year [9] Business Line Data and Key Metrics Changes - Q4 sales and marketing expenses were $20.4 million, a 101.6% increase from the same quarter last year, driven by intensified marketing and branding activities [8] - Q4 product development expenses were $1.6 million, a 72.2% increase from the same quarter last year [9] - Q4 general and administrative expenses were $5.4 million, a 123.9% increase from the same quarter last year [9] Market Data and Key Metrics Changes - Advances from students were $76.6 million at the end of the fourth quarter, indicating strong demand for educational services [10] Company Strategy and Development Direction - The company is focused on consolidating the transformational gains of the past year and enhancing user experience, with a commitment to expand growth trajectory based on the foundation built over the past years [5] - In 2026, the company expects to harvest significant front-loaded investments made in new markets, technology, and teams from 2025 [15] Management's Comments on Operating Environment and Future Outlook - Operations in the Middle East are normal, with no direct impact from the ongoing conflict, although travel restrictions and customer sentiment are being monitored [13] - The company anticipates a natural shift in lesson activity due to the Ramadan season, which falls within Q1 [14] - The company is confident that gross billings, net revenues, and operating cash flow will continue to grow healthily in 2026 [15] Other Important Information - The company's total cash equivalents and time deposits were $39.0 million at the end of the fourth quarter [9] Q&A Session Summary Question: Impact of Middle East conflict on operations and revenue exposure - Management stated that operations in the Middle East are normal, with no direct impact from the conflict, but noted travel restrictions and customer sentiment are being monitored [13] Question: Guidance or outlook for the year - Management indicated that while they do not provide official full-year guidance, they are confident that gross billings, net revenues, and operating cash flow will continue to grow healthily in 2026 [15]